Abstract: A management server according to an embodiment includes a communication part, an acquisition part, an intention estimation part, and a motion control part. The communication part communicates with one or more robot devices and one or more operation terminals that remotely operate at least one of the one or more robot devices via a network. The acquisition part acquires an operation content inputted by the operation terminal. The intention estimation part estimates an intention of an operator of the operation terminal based on the operation content acquired by the acquisition part. The motion control part controls a motion of the robot device based on an intention result estimated by the intention estimation part.

Abstract: The disclosure provides a critical care system, a critical care system control method, and a non-transitory computer-readable recording medium recording a program. A critical care system includes: a photographing device which is capable of remotely controlling at least one of a position and a direction; a critical care tool storage part which stores a critical care tool; a critical care robot which includes at least one end effector that allows for remote control; a terminal with which at least one operator remotely operates the critical care robot; and a server which is capable of acquiring medical condition information and environmental information acquired by the critical care robot, transmitting the acquired medical condition information and environmental information to the terminal, receiving operation information for the critical care robot from the terminal, and controlling the critical care robot based on the received operation information.

Abstract: The present invention provides a steel part for machine structural use whose fatigue strength and toughness are improved and a manufacturing method thereof. A steel part made of a steel containing, in mass %, C: 0.05 to 0.20%, Si: 0.10 to 1.00%, Mn: 0.75 to 3.00%, P: 0.001 to 0.050%, S: 0.001 to 0.200%, V: exceeding 0.20 to 0.25%, Cr: 0.01 to 1.00%, Al: 0.001 to 0.500%, and N: 0.0080 to 0.0200%, and a balance being composed of Fe and inevitable impurities, in which a steel structure contains a bainite structure having an area ratio of 95% or more, a bainite lath width is 5 ?m or less, V carbide having an average grain diameter of not less than 4 nm nor more than 7 nm dispersedly exists in the bainite structure, and an area ratio of V carbide in the bainite structure is 0.18% or more.

Abstract: An electric vehicle has simple structure allowing effective cooling of on-board batteries collectively disposed within a swing arm. The electric vehicle includes a swing arm that houses an electric motor that is swingably mounted to a vehicle body and drives a drive wheel WR, and batteries of a substantially rectangular parallelepiped. A wide case portion that houses the batteries is formed at a position toward a pivot shaft of the swing arm. Also, a protruding portion for forming an air reservoir space above the batteries is formed at a roof portion of the wide case portion. The batteries are disposed side by side in a front-rear direction of the vehicle body. The protruding portion, in a side view of the vehicle body, is substantially convex protruding upward across the batteries.

Abstract: A motor driven vehicle can include a swing arm swingably mounted to a vehicle body of a motor driven vehicle, and housing an electric motor driving a drive wheel of the vehicle. A pipe-like duct can have one end side connected to a hole communicating with an inside space of the swing arm, and another end side extending toward a vehicle body side. A harness, configured to drive the electric motor, can be inserted through the duct.

Abstract: The present invention provides a steel part for machine structural use whose fatigue strength and toughness are improved and a manufacturing method thereof. A steel part made of a steel containing, in mass %, C: 0.05 to 0.20%, Si: 0.10 to 1.00%, Mn: 0.75 to 3.00%, P: 0.001 to 0.050%, S: 0.001 to 0.200%, V: exceeding 0.20 to 0.25%, Cr: 0.01 to 1.00%, Al: 0.001 to 0.500%, and N: 0.0080 to 0.0200%, and a balance being composed of Fe and inevitable impurities, in which a steel structure contains a bainite structure having an area ratio of 95% or more, a bainite lath width is 5 ?m or less, V carbide having an average grain diameter of not less than 4 nm nor more than 7 nm dispersedly exists in the bainite structure, and an area ratio of V carbide in the bainite structure is 0.18% or more.

Abstract: The invention relates to an N-acyl anthranilic acid derivative or it's salt having collagen production inhibitory action.

Abstract: A drive wheel is intermediation driven by an additional element, while achieving a reduction in cost by making use of a plurality of existing motors. A drive motor as a drive source includes a plurality of motor bodies arranged coaxially with and adjacently to each other in the vehicle width direction to permit integral driving thereof, and is disposed forwardly of a pivot for a swing arm supporting the driving wheel. One end in the vehicle width direction of a drive shaft of the drive motor is made to be an output end for output to the driving wheel, and a drive sprocket for power transmission to the driving wheel is provided at the output end. The center of the drive motor in the vehicle width direction is disposed with an offset to the side opposite to the side of the drive sprocket with reference to the vehicle body center.

Abstract: The anthranilic acid derivative or the salt thereof represented by the general formula wherein R1 and R2 are hydrogen atom, or the like; R3 is a phenyl, cycloalkyl or bicyclic heterocyclic group which may be substituted, or the like; R4 is a phenyl, cycloalkyl or pyridyl group which may be substituted, or the like; X1 is an alkylene or alkenylene group which may be substituted or a bond; X2 is the general formula —X3—X4— or —X4—X3—, wherein X3 is a sulfur atom, an imino group or a bond, or the like; X4 means an alkylene or alkenylene group which may be substituted or a bond; is useful for a remedy such as rheumatoid arthritis, osteoarthritis and carcinoma, because it shows MMP—13 production inhibitory effect.

Abstract: A drive wheel is intermediation driven by an additional element, while achieving a reduction in cost by making use of a plurality of existing motors. A drive motor as a drive source includes a plurality of motor bodies arranged coaxially with and adjacently to each other in the vehicle width direction to permit integral driving thereof, and is disposed forwardly of a pivot for a swing arm supporting the driving wheel. One end in the vehicle width direction of a drive shaft of the drive motor is made to be an output end for output to the driving wheel, and a drive sprocket for power transmission to the driving wheel is provided at the output end. The center of the drive motor in the vehicle width direction is disposed with an offset to the side opposite to the side of the drive sprocket with reference to the vehicle body center.

Abstract: An electric vehicle has simple structure allowing effective cooling of on-board batteries collectively disposed within a swing arm. The electric vehicle includes a swing arm that houses an electric motor that is swingably mounted to a vehicle body and drives a drive wheel WR, and batteries of a substantially rectangular parallelepiped. A wide case portion that houses the batteries is formed at a position toward a pivot shaft of the swing arm. Also, a protruding portion for forming an air reservoir space above the batteries is formed at a roof portion of the wide case portion. The batteries are disposed side by side in a front-rear direction of the vehicle body. The protruding portion, in a side view of the vehicle body, is substantially convex protruding upward across the batteries.

Abstract: A motor driven vehicle can include a swing arm swingably mounted to a vehicle body of a motor driven vehicle, and housing an electric motor driving a drive wheel of the vehicle. A pipe-like duct can have one end side connected to a hole communicating with an inside space of the swing arm, and another end side extending toward a vehicle body side. A harness, configured to drive the electric motor, can be inserted through the duct.

Abstract: A powder-particle dosage form obtained by granulating an excipient and/or a disintegrating agent with a liquid in which a bitter taste masking base is dissolved and/or suspended, and a drug having solubility in water (20° C.) of not higher than 1 g/mL is dissolved or suspended, or a tablet obtained by compressing the powder-particle dosage form could mask bitter taste of a drug.

Abstract: An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R1 represents a carboxyl group or the like; R2 represents a hydrogen atom or the like; R3 represents an optionally substituted aryl group or the like; X1 represents a carbonyl group; X2 represents a bonding hand; X3 represents a bonding hand; X4 represents a bonding hand or the like; and A represents an optionally substituted phenyl group or the like.

Abstract: An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substituted phenyl, a monocyclic heterocyclic group, etc.; X1 represents carbonyl, etc.; X2 represents optionally substituted alkylene group, a bond, etc.; X3 represents oxygen, a bond, etc.; and X4 represents a group represented by the general formula —X5—X6— or —X6—X5— (wherein X5 means oxygen, a bond, etc.; and X6 means optionally substituted alkylene, a bond, etc.)] or a salt of the derivative. The derivative or salt has the inhibitory activity of MMP-13 production and is hence useful as a therapeutic agent for articular rheumatism, osteoarthritis, cancer, etc.

Abstract: A powder•particle dosage form obtained by granulating an excipient and/or a disintegrating agent with a liquid in which a bitter taste masking base is dissolved and/or suspended, and a drug having solubility in water (20° C.) of not higher than 1 g/mL is dissolved or suspended, or a tablet obtained by compressing the powder•particle dosage form could mask bitter taste of a drug.

Abstract: An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substituted phenyl, a monocyclic heterocyclic group, etc.; X1 represents carbonyl, etc.; X2 represents optionally substituted alkylene group, a bond, etc.; X3 represents oxygen, a bond, etc.; and X4 represents a group represented by the general formula -X5-X6- or -X6-X5- (wherein X5 means oxygen, a bond, etc.; and X6 means optionally substituted alkylene, a bond, etc.)] or a salt of the derivative. The derivative or salt has the inhibitory activity of MMP-13 production and is hence useful as a therapeutic agent for articular rheumatism, osteoarthritis, cancer, etc.

Abstract: The anthranilic acid derivative or the salt thereof represented by the general formula wherein R1 and R2 are hydrogen atom, or the like; R3 is a phenyl, cycloalkyl or bicyclic heterocyclic group which may be substituted, or the like; R4 is a phenyl, cycloalkyl or pyridyl group which may be substituted, or the like; X1 is an alkylene or alkenylene group which may be substituted or a bond; X2 is the general formula -X3-X4- or -X4-X3-, wherein X3 is a sulfur atom, an imino group or a bond, or the like; X4 means an alkylene or alkenylene group which may be substituted or a bond; is useful for a remedy such as rheumatoid arthritis, osteoarthritis and carcinoma, because it shows MMP-13 production inhibitory effect.

Abstract: Autoimmune diseases, cell adhesion inhibition and immunomodulation are treated or effected by a method, comprising, treating a patient with a therapeutically effective amount of a 4H-1-benzopyran-4-one compound represented by the following formula or a salt thereof: ##STR1## wherein R.sup.1 is an unsubstituted or halogen-substituted alkyl, alkenyl or aryl group; R.sup.2 is a hydrogen atom or an alkyl or acyl group; R.sup.3 is a hydrogen or halogen atom or a cyano, azido, carboxyl, hydroxyl, formyl or alkoxycarbonyl group or a substituted or unsubstituted alkyl, alkoxy, phenoxy, cycloalkyl, carbamoyl, amino or phenyl group; R.sup.4 is a hydrogen or halogen atom, a nitro, cyano, carboxyl, acyl, hydroxyl or alkoxycarbonyl group, or a substituted or unsubstituted alkyl, alkoxy, alkylthio, phenylthio, alkynyl, alkenyl, sulfamoyl, alkanesulfonyl, alkanesulfonyl, amidino, phenyl or heterocyclic group or a group of the formula ##STR2## where R.sup.

Abstract: A 4H-1-benzopyran-4-one derivative of the general formura ?1!, ##STR1## or a salt thereof exerts excellent effects on immunomodulation and cell adhesion inhibition, and is further expected to have the effect of relieving autoimmune diseases at a level comparable to that of steroids. Thus, the compound of the general formula ?1! is useful in the teatment and prevention of autoimmune diseases fundamentally caused by immunopathy or unusually accelerated cell adhesion, for example, chronic rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease,polyarteritis nodosa, polymyositis/dermatomyositis, Sjogren's syndrome, Behcet's disease, multiple sclerosis, autoimmune diabetes, Hashimoto's disease, psoriasis, primary myxedema, pernicious anemia, serious adynamia, ulcerative colitis, chronic active hepatitis, autoimmune hemolytic anemia idiopathic thrombocytopenic purpura and the like.